https://www.selleckchem.com/pr....oducts/nazartinib-eg
We applied the restricted mean survival time (RMST) to analyse the survival data reported in the PARADIGM-HT trial in which sacubitril+valsartan was studied in comparison with enalapril in patients with heart failure. The estimates of this parameter were compared with the published values of hazard ratio (HR). Two endpoints were evaluated a composite of death or hospitalization and cardiovascular death. Our analyses were performed by considering the original follow-up of 41.4months and on the basis of a lifetime perspe
Like
Comment
Share
